Spironolactone and hydrochlorothiazide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Spironolactone and hydrochlorothiazide
• 英文别名: 6-chloro-1,1-dioxo-3,4-dihydro-2H-1λ6,2,4-benzothiadiazine-7-sulfonamide;S-[(7R,8R,9S,10R,13S,14S,17R)-10,13-dimethyl-3,5'-dioxospiro[2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthrene-17,2'-oxolane]-7-yl] ethanethioate
• 化学式: C31H40ClN3O8S3
• 分子量: 714.3
• InChiKey: RFNRSUBWOXSCLB-FXFKJASFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  46
• 可旋转键数：
  3
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  221
• 氢给体数：
  3
• 氢受体数：
  12

文献信息

• Method for treating resistant hypertension
  申请人：Gerber Michael J.

  公开号：US20070196510A1

  公开（公告）日：2007-08-23

  A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.

  提供了一种降低临床诊断为顽固性高血压患者血压的方法。该方法包括将达卢生坦作为辅助药物与基础抗高血压治疗方案联合给药，该基础方案包括至少一种利尿剂和至少两种抗高血压药物，这些药物选自至少两类：(a) ACE抑制剂和血管紧张素II受体阻滞剂，(b) β-肾上腺素能受体阻滞剂，以及(c) 钙通道阻滞剂。达卢生坦以有效剂量和频率口服给药，与基础治疗方案结合，能够使选自谷值坐位收缩压、谷值坐位舒张压、24小时动态收缩压、24小时动态舒张压、日间最高收缩压和日间最高舒张压的一个或多个血压参数至少降低约3 mmHg。
• THERAPY FOR COMPLICATIONS OF DIABETES
  申请人：Roden Robert L.

  公开号：US20090054473A1

  公开（公告）日：2009-02-26

  A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ET A ) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ET A receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ET A receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ET A receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ET A receptor antagonist.

  一种增强患有糖尿病肾病和/或代谢综合征的人类受试者的血糖控制和/或胰岛素敏感性的方法，包括向该受试者施用一种选择性内皮素A（ETA）受体拮抗剂，其剂量足以增强血糖控制和/或胰岛素敏感性。一种治疗老年糖尿病人类受试者中复合共病的方法，包括向该受试者施用一种选择性ETA受体拮抗剂，与至少一种其他药物联合或作为辅助治疗，该其他药物（i）不是选择性ETA受体拮抗剂，且（ii）在治疗糖尿病和/或至少一种除高血压外的上述共病中有效。适用于此类方法的治疗组合包括一种选择性ETA受体拮抗剂和至少一种非选择性ETA受体拮抗剂的抗糖尿病、抗肥胖或抗血脂异常药物。
• ANTIHYPERTENSIVE THERAPY
  申请人：Gerber Michael J.

  公开号：US20090221549A1

  公开（公告）日：2009-09-03

  A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is orally deliverable and/or (b) the daily dose of darusentan is effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures. Further provided is a new use of darusentan in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy, wherein the composition is administered adjunctively with at least one diuretic and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers.

  提供了一种新的达卢生坦用途，用于制备一种药用组合物，旨在降低对一种或多种药物的基础抗高血压治疗表现出抵抗性的患者的血压。该组合物包含达卢生坦，其剂量提供了治疗上有效的每日剂量；其中（a）该组合物可通过口服给药，和/或（b）达卢生坦的每日剂量有效，能在一项或多项选自谷底坐位收缩压、谷底坐位舒张压、24小时动态收缩压、24小时动态舒张压、日间最高收缩压和日间最高舒张压的血压参数中至少降低约3mmHg。还提供了一种新的达卢生坦用途，用于制备一种药用组合物，旨在降低对基础抗高血压治疗表现出抵抗性的患者的血压，其中该组合物与至少一种利尿剂和至少一种选自ACE抑制剂、血管紧张素II受体阻滞剂、β-肾上腺素能受体阻滞剂和钙通道阻滞剂的抗高血压药物联合给药。
• Methods of treating a subject for a condition
  申请人：PALO ALTO INVESTORS

  公开号：US10086071B2

  公开（公告）日：2018-10-02

  Methods are provided for treating a subject for at least one condition that includes inflammation, a blood clotting condition and autonomic nervous system dysfunction such as adrenergia, e.g., simultaneously. Also provided are kits for use in practicing the subject methods.

  提供了治疗受试者至少一种病症的方法，这些病症包括炎症、凝血病症和自律神经系统功能障碍，如肾上腺机能亢进症，例如，同时治疗。还提供了用于实施上述方法的试剂盒。
• Treatment of conditions through pharmacological modulation of the autonomic nervous system
  申请人：Palo Alto Investors

  公开号：US10702533B2

  公开（公告）日：2020-07-07

  Methods are provided for treating a subject for a condition caused by an abnormality in the subject's autonomic nervous system. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is pharmacologically modulated with at least one beta-blocker in a manner that is effective to treat the subject for the condition. The subject methods find use in the treatment of a variety of different conditions, where such conditions include various disease conditions. Also provided are systems and kits for use in practicing the subject methods.

  本研究提供了治疗受试者自律神经系统异常引起的疾病的方法。根据这些方法，用至少一种β-受体阻滞剂对受试者自律神经系统的至少一部分进行药理学调节，这种调节方式可有效治疗受试者的病症。这些方法可用于治疗各种不同的病症，这些病症包括各种疾病。此外，还提供了用于实施上述方法的系统和试剂盒。